Kidney transplant from hepatitis C viremic donors into aviremic recipients and risk for post-transplant BK and cytomegalovirus infection.
BK virus
acute rejection
cytomegalovirus
donor-specific antibodies
hepatitis C
kidney transplant
Journal
Transplant infectious disease : an official journal of the Transplantation Society
ISSN: 1399-3062
Titre abrégé: Transpl Infect Dis
Pays: Denmark
ID NLM: 100883688
Informations de publication
Date de publication:
Aug 2022
Aug 2022
Historique:
revised:
06
04
2022
received:
02
03
2022
accepted:
16
04
2022
pubmed:
27
6
2022
medline:
13
8
2022
entrez:
26
6
2022
Statut:
ppublish
Résumé
kidney transplantation from Hepatitis C virus (HCV) viremic donors to uninfected recipients is associated with excellent short-term outcomes. However, HCV viremia might be associated with an increased risk for post-transplant viral complications. We designed a retrospective study of HCV-negative kidney-only transplant recipients between 2018 and 2020. Recipients were grouped into group 1; HCV-negative donors, and group 2; HCV-viremic donors. Patients were matched 1:1 using propensity score. The primary objectives were to compare the incidence of cytomegalovirus (CMV) viremia ≥ 200 ml/IU, and BK viremia ≥1000 copies/ml between the groups. Secondary outcomes included group comparison of CMV disease, BK viremia ≥10 000 copies/ml, and 1-year patient and allograft survival. The study included 634 patients in group 1, and 71 patients in group 2. Sixty-five pairs of patients were matched. Incidence of CMV viremia (33.3% vs. 40.0%, p = .4675), and BK viremia (15.9% vs. 27.7%, p = .1353) did not differ significantly between groups in the matched cohort. Incidence of CMV disease (81.0% vs. 76.9%, p = 1.000), and BK viremia ≥10 000 copies/ml (9.5% vs. 16.9%, p = .2987) were comparable between groups. There was no difference in the 1-year patient or allograft survival between groups. kidney transplant from HCV-viremic donors is not associated with increased risk for BK or CMV viremia.
Sections du résumé
BACKGROUND
BACKGROUND
kidney transplantation from Hepatitis C virus (HCV) viremic donors to uninfected recipients is associated with excellent short-term outcomes. However, HCV viremia might be associated with an increased risk for post-transplant viral complications.
METHODS
METHODS
We designed a retrospective study of HCV-negative kidney-only transplant recipients between 2018 and 2020. Recipients were grouped into group 1; HCV-negative donors, and group 2; HCV-viremic donors. Patients were matched 1:1 using propensity score. The primary objectives were to compare the incidence of cytomegalovirus (CMV) viremia ≥ 200 ml/IU, and BK viremia ≥1000 copies/ml between the groups. Secondary outcomes included group comparison of CMV disease, BK viremia ≥10 000 copies/ml, and 1-year patient and allograft survival.
RESULTS
RESULTS
The study included 634 patients in group 1, and 71 patients in group 2. Sixty-five pairs of patients were matched. Incidence of CMV viremia (33.3% vs. 40.0%, p = .4675), and BK viremia (15.9% vs. 27.7%, p = .1353) did not differ significantly between groups in the matched cohort. Incidence of CMV disease (81.0% vs. 76.9%, p = 1.000), and BK viremia ≥10 000 copies/ml (9.5% vs. 16.9%, p = .2987) were comparable between groups. There was no difference in the 1-year patient or allograft survival between groups.
CONCLUSION
CONCLUSIONS
kidney transplant from HCV-viremic donors is not associated with increased risk for BK or CMV viremia.
Substances chimiques
Antiviral Agents
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
e13887Informations de copyright
© 2022 Wiley Periodicals LLC.
Références
Levitsky J, Formica RN, Bloom RD, et al. The American Society of Transplantation consensus conference on the use of Hepatitis C viremic donors in solid organ transplantation. Am J Transplant. 2017;17(11):2790-2802.
Durand CM, Bowring MG, Brown DM, et al. Direct-acting antiviral prophylaxis in kidney transplantation from Hepatitis C virus-infected donors to noninfected recipients: an open-label nonrandomized trial. Ann Intern Med. 2018;168(8):533-540.
Goldberg DS, Abt PL, Blumberg EA, et al. Trial of transplantation of HCV-infected kidneys into uninfected recipients. N Engl J Med. 2017;376(24):2394-2395.
Molnar MZ, Nair S, Cseprekal O, et al. Transplantation of kidneys from hepatitis C-infected donors to hepatitis C-negative recipients: single center experience. Am J Transplant. 2019;19(11):3046-3057.
Sise ME, Goldberg DS, Kort JJ, et al. Multicenter study to transplant Hepatitis C-infected kidneys (MYTHIC): an open-label study of combined glecaprevir and pibrentasvir to treat recipients of transplanted kidneys from deceased donors with Hepatitis C virus infection. J Am Soc Nephrol. 2020;31(11):2678-2687.
Daloul R, Anthony M, Washburn K, Singh P, Pesavento T. A real-world, single-center experience of the utilization of hepatitis C-viremic kidneys for hepatitis C-negative recipients. Clin Nephrol. 2021;96(4):216-225.
Kapila N, Menon KVN, Al-Khalloufi K, et al. Hepatitis C virus NAT-positive solid organ allografts transplanted into Hepatitis C virus-negative recipients: a real-world experience. Hepatology. 2020;72(1):32-41.
Jandovitz N, Nair V, Grodstein E, et al. Hepatitis C-positive donor to negative recipient kidney transplantation: a real-world experience. Transpl Infect Dis. 2020:e13540.
La Hoz RM, Sandikci B, Ariyamuthu VK, Tanriover B. Short-term outcomes of deceased donor renal transplants of HCV uninfected recipients from HCV seropositive nonviremic donors and viremic donors in the era of direct-acting antivirals. Am J Transplant. 2019;19(11):3058-3070.
Potluri VS, Goldberg DS, Mohan S, et al. National trends in utilization and 1-year outcomes with transplantation of HCV-viremic kidneys. J Am Soc Nephrol. 2019;30(10):1939-1951.
Molnar MZ, Azhar A, Tsujita M, et al. Transplantation of kidneys from Hepatitis C virus-infected donors to Hepatitis C virus-negative recipients: one-year kidney allograft outcomes. Am J Kidney Dis. 2021;77(5):739-747 e731.
Cannon RM, Locke JE, Orandi BJ, et al. Impact of donor Hepatitis C virus on kidney transplant outcomes for Hepatitis C-positive recipients in the direct-acting antiviral era: time to revise the kidney donor risk index? Transplantation. 2020;104(6):1215-1228.
Reese PP, Abt PL, Blumberg EA, et al. Twelve-month outcomes after transplant of Hepatitis C-infected kidneys into uninfected recipients: a single-group trial. Ann Intern Med. 2018;169(5):273-281.
Daloul R, Pesavento T, Goldberg DS, Reese PP. A review of kidney transplantation from HCV-viremic donors into negative recipients. Kidney Int. 2021;100(6):1190-1198.
Daloul R, Pesavento T, Michaels A. Expanding the use of HCV infected organs and the challenge of third-party payers. Am J Transplant. 2020;20(5):1463-1464.
Torabi J, Rocca JP, Ajaimy M, et al. Commercial insurance delays direct-acting antiviral treatment for hepatitis C kidney transplantation into uninfected recipients. Transpl Infect Dis. 2020:e13449.
Christiaansen A, Varga SM, Spencer JV. Viral manipulation of the host immune response. Curr Opin Immunol. 2015;36:54-60.
Pollmann J, Rolle A, Hofmann M, Cerwenka A. Hepatitis C virus and human cytomegalovirus-natural killer cell subsets in persistent viral infections. Front Immunol. 2017;8:566.
Yao ZQ, King E, Prayther D, Yin D, Moorman J. T cell dysfunction by hepatitis C virus core protein involves PD-1/PDL-1 signaling. Viral Immunol. 2007;20(2):276-287.
Zhao BB, Zheng SJ, Gong LL, et al. T lymphocytes from chronic HCV-infected patients are primed for activation-induced apoptosis and express unique pro-apoptotic gene signature. PLoS One. 2013;8(10):e77008.
Lucas M, Vargas-Cuero AL, Lauer GM, et al. Pervasive influence of hepatitis C virus on the phenotype of antiviral CD8+ T cells. J Immunol. 2004;172(3):1744-1753.
Khan ST, Karges W, Cooper CL, Crawley AM. Hepatitis C virus core protein reduces CD8(+) T-cell proliferation, perforin production and degranulation but increases STAT5 activation. Immunology. 2018;154(1):156-165.
Large MK, Kittlesen DJ, Hahn YS. Suppression of host immune response by the core protein of hepatitis C virus: possible implications for hepatitis C virus persistence. J Immunol. 1999;162(2):931-938.
Bodro M, Londono MC, Esforzado N, et al. Hepatitis C viremia as a risk factor for opportunistic infections in kidney transplant recipients. Clin Transplant. 2018;32(10):e13382.
Bodro M, Sanclemente G, Crespo G, et al. Severe Hepatitis C recurrence as a risk factor for opportunistic infections in liver transplant recipients. Transplant Proc. 2018;50(5):1437-1443.
Martin B, Hennecke N, Lohmann V, et al. Restoration of HCV-specific CD8+ T cell function by interferon-free therapy. J Hepatol. 2014;61(3):538-543.
Vranjkovic A, Deonarine F, Kaka S, Angel JB, Cooper CL, Crawley AM. Direct-acting antiviral treatment of HCV infection does not resolve the dysfunction of circulating CD8(+) T-cells in advanced liver disease. Front Immunol. 2019;10:1926.
Arthurs SK, Eid AJ, Pedersen RA, et al. Delayed-onset primary cytomegalovirus disease and the risk of allograft failure and mortality after kidney transplantation. Clin Infect Dis. 2008;46(6):840-846.
Borchers AT, Perez R, Kaysen G, Ansari AA, Gershwin ME. Role of cytomegalovirus infection in allograft rejection: a review of possible mechanisms. Transpl Immunol. 1999;7(2):75-82.
Hjelmesaeth J, Sagedal S, Hartmann A, et al. Asymptomatic cytomegalovirus infection is associated with increased risk of new-onset diabetes mellitus and impaired insulin release after renal transplantation. Diabetologia. 2004;47(9):1550-1556.
Sagedal S, Hartmann A, Nordal KP, et al. Impact of early cytomegalovirus infection and disease on long-term recipient and kidney graft survival. Kidney Int. 2004;66(1):329-337.
Leeaphorn N, Garg N, Thamcharoen N, Khankin EV, Cardarelli F, Pavlakis M. Cytomegalovirus mismatch still negatively affects patient and graft survival in the era of routine prophylactic and preemptive therapy: a paired kidney analysis. Am J Transplant. 2019;19(2):573-584.
Kuo HT, Ye X, Sampaio MS, Reddy P, Bunnapradist S. Cytomegalovirus serostatus pairing and deceased donor kidney transplant outcomes in adult recipients with antiviral prophylaxis. Transplantation. 2010;90(10):1091-1098.
Brennan DC, Agha I, Bohl DL, et al. Incidence of BK with tacrolimus versus cyclosporine and impact of preemptive immunosuppression reduction. Am J Transplant. 2005;5(3):582-594.
Bressollette-Bodin C, Coste-Burel M, Hourmant M, Sebille V, Andre-Garnier E, Imbert-Marcille BM. A prospective longitudinal study of BK virus infection in 104 renal transplant recipients. Am J Transplant. 2005;5(8):1926-1933.
Jamboti JS. BK virus nephropathy in renal transplant recipients. Nephrology (Carlton). 2016;21(8):647-654.
Bohl DL, Brennan DC. BK virus nephropathy and kidney transplantation. Clin J Am Soc Nephrol. 2007;2(Suppl 1):S36-46.
Parajuli S, Astor BC, Kaufman D, et al. Which is more nephrotoxic for kidney transplants: BK nephropathy or rejection? Clin Transplant. 2018;32(4):e13216.
Mohamed M, Parajuli S, Muth B, et al. In kidney transplant recipients with BK polyomavirus infection, early BK nephropathy, microvascular inflammation, and serum creatinine are risk factors for graft loss. Transpl Infect Dis. 2016;18(3):361-371.
Nickeleit V, Singh HK, Randhawa P, et al. The Banff Working Group classification of definitive polyomavirus nephropathy: morphologic definitions and clinical correlations. J Am Soc Nephrol. 2018;29(2):680-693.
Lopez-Medrano F, Fernandez-Ruiz M, Morales JM, et al. Impact of hepatitis C virus infection on the risk of infectious complications after kidney transplantation: data from the RESITRA/REIPI cohort. Transplantation. 2011;92(5):543-549.
Yazawa M, Fulop T, Cseprekal O, et al. The incidence of cytomegalovirus infection after deceased-donor kidney transplantation from hepatitis-C antibody positive donors to hepatitis-C antibody negative recipients. Ren Fail. 2020;42(1):1083-1092.
Molnar MZ, Potluri VS, Schaubel DE, et al. Association of donor hepatitis C virus infection status and risk of BK polyomavirus viremia after kidney transplantation. Am J Transplant. 2021.